Abstract
Introduction Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. Methods Serial T1-weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point. Results Atrophy increased after the change-point, which occurred 1–1.5 years (assuming a single step change in atrophy rate) or 3–8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change-point. Discussion Atrophy rates are pathologically increased up to seven years before “expected onset”. During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
Original language | English (US) |
---|---|
Pages (from-to) | 43-53 |
Number of pages | 11 |
Journal | Alzheimer's and Dementia |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2018 |
Keywords
- Alzheimer's disease
- Atrophy
- Autosomal dominant
- Boundary Shift Integral
- Change-point
- Dementia
- Longitudinal
- MRI
- Neuroimaging
- Nonlinear modeling
ASJC Scopus subject areas
- Clinical Neurology
- Geriatrics and Gerontology
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
- Health Policy
- Developmental Neuroscience
- Epidemiology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Presymptomatic atrophy in autosomal dominant Alzheimer's disease : A serial magnetic resonance imaging study. / For the; Dominantly Inherited Alzheimer Network (DIAN).
In: Alzheimer's and Dementia, Vol. 14, No. 1, 01.2018, p. 43-53.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Presymptomatic atrophy in autosomal dominant Alzheimer's disease
T2 - A serial magnetic resonance imaging study
AU - For the
AU - Dominantly Inherited Alzheimer Network (DIAN)
AU - Kinnunen, Kirsi M.
AU - Cash, David M.
AU - Poole, Teresa
AU - Frost, Chris
AU - Benzinger, Tammie L.S.
AU - Ahsan, R. Laila
AU - Leung, Kelvin K.
AU - Cardoso, M. Jorge
AU - Modat, Marc
AU - Malone, Ian B.
AU - Morris, John C.
AU - Bateman, Randall J.
AU - Marcus, Daniel S.
AU - Goate, Alison
AU - Salloway, Stephen P.
AU - Correia, Stephen
AU - Sperling, Reisa A.
AU - Chhatwal, Jasmeer P.
AU - Mayeux, Richard P.
AU - Brickman, Adam M.
AU - Martins, Ralph N.
AU - Farlow, Martin R.
AU - Ghetti, Bernardino
AU - Saykin, Andrew J.
AU - Jack, Clifford R.
AU - Schofield, Peter R.
AU - McDade, Eric
AU - Weiner, Michael W.
AU - Ringman, John M.
AU - Thompson, Paul M.
AU - Masters, Colin L.
AU - Rowe, Christopher C.
AU - Rossor, Martin N.
AU - Ourselin, Sebastien
AU - Fox, Nick C.
N1 - Funding Information: The study sponsors had no role in any aspects of designing or executing this study. The authors had full access to the data used in the study and made the final decision to submit for publication. Data collection and sharing for this project was supported by the Dominantly Inherited Alzheimer's Network (DIAN, U19AG032438), funded by the National Institute on Aging, the National Institute for Health Research (NIHR), Queen Square Dementia Biomedical Research Unit, the Alzheimer's Society (AS-PG-205), and the Medical Research Council's (MRC) Dementias Platform UK (DPUK). The present study was undertaken at UCLH/UCL, who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre's funding scheme. The Dementia Research Centre (DRC) is supported by the UK Dementia Research Institute, Alzheimer's Research UK (ARUK), Brain Research Trust, and The Wolfson Foundation. The DRC is also an ARUK coordinating centre and has received equipment funded by ARUK and the Brain Research Trust. K.M.K. reports grants from Anonymous Foundation, during the conduct of the study; grants from ARUK (ARUK-PCRF2014B-1), outside the submitted work. D.M.C. reports grants from Anonymous Foundation and the Alzheimer's Society (AS-PG-15-025), during the conduct of the study; grants from Anonymous Foundation, Alzheimer's Research UK, and Medical Research Council outside the submitted work. CF received a grant from the Institute of Neurology, UCL that funded the work reported here. He also reports grants from NIHR, the Economic and Social Research Council, Effective Intervention, the Multiple Sclerosis Trials Collaboration and Oxford University, and consultancy payments from CSL Behring, all for work unrelated to this paper. T.L.S.B. reports grants from National Institutes of Health (NIH) (U19AG032438, UL1TR000448, and 5P30NS04805), during the conduct of the study; grants from Avid Radiopharmaceuticals (Eli Lilly), other from Avid Radiopharmaceuticals (Eli Lilly), other from Roche, other from Medscape LLC, and other from Quintiles, outside the submitted work. J.C.M. reports grants from NIH (P50AG005681, P01AG003991, P01AG026276, and U19AG032438), during the conduct of the study. M.N.R. reports personal fees from Servier, grants from National Institute for Health Research (NIHR), DIAN, GENFI, and DPUK, outside the submitted work. N.C.F. reports personal fees (all paid to University College London directly) from Janssen/Pfizer, GE Healthcare, IXICO, Johnson & Johnson, Genzyme, Eisai, Janssen Alzheimer's Immunotherapy Research and Development, Lilly Research Laboratories (AVID) and Eli Lilly, and Novartis Pharma AG, outside the submitted work. In addition, N.C.F. has a patent QA Box issued. R.J.B. reports grants from NIH/NIA U19 AG032438 and Anonymous Foundation, during the conduct of the study; grants from the Alzheimer's Association, American Academy of Neurology, Anonymous Foundation, AstraZeneca, BrightFocus Foundation, Cure Alzheimer's Fund, Glenn Foundation for Medical Research, Merck, Metropolitan Life Foundation, NIH, grants from Pharma Consortium (Biogen Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-Roche Inc., Genentech Inc., Janssen Alzheimer Immunotherapy, Mithridion Inc., Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, and Eisai), Roche, Ruth K. Broadman Biomedical Research Foundation, NIH/NINDS 2R01NS065667-05, Alzheimer's Association, NIH/NIA (5K23AG030946, P50AG05681), nonfinancial support from Avid Radiopharmaceuticals, other from C2N Diagnostics, NIH and NIH/State Government Sources, personal fees and other from Washington University, personal fees and nonfinancial support from Roche, IMI, Sanofi, Global Alzheimer's Platform, FORUM, OECD, and Boehringer Ingelheim, personal fees from Merck, outside the submitted work. S.S. reports grants and personal fees from Lilly, Biogen, Genentech, Roche, and Merck, personal fees from Piramal and Forum, grants from GE and Avid, outside the submitted work. A.G. reports grants from NIH and Anonymous Foundation, during the conduct of the study; personal fees from Cognition Therapeutics and Amgen, grants and nonfinancial support from Genentech, grants from DIAN Pharma Consortium, outside the submitted work. In addition, A.G. has a patent (6,083,694, 5,973,133) issued. R.A.S. reports grants from National Institute on Aging, Eli Lilly, Janssen, Bristol Myers Squibb, American Health Assistance Foundation, and Alzheimer's Association, during the conduct of the study; personal fees from Eisa, Merck, Boehringer-Ingelheim, Genentech, Roche, Isis, Janssen, Biogen, and Avid Radiopharmaceuticals, outside the submitted work. A.M.B. reports grants from NIH (AG034189, AG043337, AG016495, AG036469, AG037212), during the conduct of study; personal fees from Keystone Heart, personal fees from ProPhase, outside the submitted work. M.R.F., B.G., and A.J.S. were supported by NIH grant P30 AG010133 during the study; A.J.S. was supported by additional NIH grants (R01 AG019771, R01 LM011360, R44 AG049540, R01 CA129769, and U01 AG032984) during the conduct of the study, and also received grant support from Eli Lilly and PET tracer support from Avid Radiopharmaceuticals, outside the submitted work. C.R.J. reports grants from NIH, Alexander Family Alzheimer's Disease professorship of the Mayo Foundation, other from Eli Lilly, outside the submitted work. PRS reports grants from NIA, Anonymous Foundation, and Wicking and Mason Trusts, during the conduct of the study; personal fees from ICMI Speakers & Entertainers and Janssen-Cilag Pty Ltd, outside the submitted work. M.W.W. reports grants from DOD, NIH/NIA, Veterans Administration, Alzheimer's Association, and Alzheimer's Drug Discovery Foundation, during the conduct of the study; personal fees from Synarc, Janssen, Alzheimer's Drug Discovery Foundation, Neurotrope Bioscience, Merck, Avid, Biogen Idec, Genentech, and Eli Lilly, outside the submitted work. J.M.R. reports grants from NIH, during the conduct of the study; other from Biogen Idec, other from Eli-Lilly, outside the submitted work. All other authors have nothing to disclose. C.C.R. reports personal fees from Roche and GE Healthcare, grants from GE Healthcare, Avid Radiopharmaceuticals and Piramal Imaging, outside the submitted work. S.O. is funded by the Engineering and Physical Sciences Research Council (EP/H046410/1, EP/J020990/1, EP/K005278), the Medical Research Council (MR/J01107X/1), the EU-FP7 project VPH-DARE@IT (FP7- ICT-2011-9-601055), and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR BRC UCLH/UCL High Impact Initiative BW.mn.BRC10269. Publisher Copyright: © 2017 the Alzheimer's Association
PY - 2018/1
Y1 - 2018/1
N2 - Introduction Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. Methods Serial T1-weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point. Results Atrophy increased after the change-point, which occurred 1–1.5 years (assuming a single step change in atrophy rate) or 3–8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change-point. Discussion Atrophy rates are pathologically increased up to seven years before “expected onset”. During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
AB - Introduction Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. Methods Serial T1-weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed-effects models estimated the change-points when atrophy rates deviate from normal and the rates of change before and after this point. Results Atrophy increased after the change-point, which occurred 1–1.5 years (assuming a single step change in atrophy rate) or 3–8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change-point. Discussion Atrophy rates are pathologically increased up to seven years before “expected onset”. During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
KW - Alzheimer's disease
KW - Atrophy
KW - Autosomal dominant
KW - Boundary Shift Integral
KW - Change-point
KW - Dementia
KW - Longitudinal
KW - MRI
KW - Neuroimaging
KW - Nonlinear modeling
UR - http://www.scopus.com/inward/record.url?scp=85028299863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028299863&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2017.06.2268
DO - 10.1016/j.jalz.2017.06.2268
M3 - Article
C2 - 28738187
AN - SCOPUS:85028299863
SN - 1552-5260
VL - 14
SP - 43
EP - 53
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 1
ER -